BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Business

  Report: Multiple Suitors - Including BMS - Vied for Acceleron’s Attention

  Merck and Acceleron struck an $11.5 billion merger agreement, but before that, rare-disease focused Acceleron Pharma was wooed by multiple suitors, including pharma giant Bristol Myers Squibb.

  October 14, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Research Roundup: T-Cell Immune Response to COVID-19 Vaccines and More

  Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

  October 14, 2021

   · 

  5 min read

   · 

  Mark Terry
• 

  Business

  Hemostemix Announces Dr. Fraser C. Henderson Sr., MD, as Chief Medical Officer

  Dr. Fraser C. Henderson Sr. is an exceptional neurological surgeon with extensive experience and expertise in all facets of neurosurgery and neurological science.

  October 14, 2021

   · 

  9 min read
• 

  Drug Development

  COVID Update: Mixing COVID-19 Vaccines Safe and Effective; Biden Presses Moderna

  As the FDA prepares to discuss booster shots for Moderna and J&J vaccines, a new study came out suggesting that mixing and matching vaccines works well and is safe.

  October 14, 2021

   · 

  4 min read

   · 

  Mark Terry
• 

  Business

  Amazon and Big Pharma Unite to Propel AI Innovation in Therapeutics

  Four leading pharmaceutical companies partnered with Amazon Web Services and Israel Biotech Fund to launch AION Labs, an innovation space that will allow drug developers to harness AI and computational science to solve therapeutic challenges.

  October 14, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Merck’s Keytruda Notches Win in First-Line Cervical Cancer

  Today’s approval was based on the Phase III KEYNOTE-826 trial that evaluated Keytruda and chemotherapy with or without bevacizumab compared to the same chemotherapy treatment.

  October 14, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Rectify Nets $100 Million to Help the Body Relearn its ABCs

  Rectify emerged with a goal to develop disease-modifying precision therapies that will restore ABC transporter function in order to address the underlying cause of serious genetic disease.

  October 14, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Broad Institute Names Chief Equity Officer in Commitment to Inclusive Medicine

  Broad announced that it is bringing René Salazar on board as its first chief equity officer.

  October 14, 2021

   · 

  3 min read

   · 

  Heather McKenzie
• 

  FDA

  With No Clear Path Forward, Ardelyx Will Axe 102 More Jobs

  The FDA gave Ardelyx a CRL on the NDA but did not mention anything about clinical pharmacology or biopharmaceutics, safety, or any related non-clinical concerns.

  October 14, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  A New Pathway to Solving Chronic Neurological Diseases - Maybe Long COVID?

  CT38 is being studied in myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS), as well as in fibromyalgia and chronic Lyme disease.

  October 14, 2021

   · 

  5 min read

   · 

  Heather McKenzie